Audeo Oncology (Audeo Oncology) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Audeo Oncology's cash to debt ratio for the quarter that ended in Sep. 2012 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Audeo Oncology could pay off its debt using the cash in hand for the quarter that ended in Sep. 2012.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Audeo Oncology's Cash-to-Debt or its related term are showing as below:

AURX's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.95
* Ranked among companies with meaningful Cash-to-Debt only.

Audeo Oncology Cash-to-Debt Historical Data

The historical data trend for Audeo Oncology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Audeo Oncology Cash-to-Debt Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Cash-to-Debt

No Debt

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Cash-to-Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Audeo Oncology's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Audeo Oncology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Cash-to-Debt falls into.

Audeo Oncology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Audeo Oncology's Cash to Debt Ratio for the fiscal year that ended in Jun. 2012 is calculated as:

Audeo Oncology had no debt ⁽¹⁾.

Audeo Oncology's Cash to Debt Ratio for the quarter that ended in Sep. 2012 is calculated as:

Audeo Oncology had no debt ⁽¹⁾.

Audeo Oncology (DELISTED:AURX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Audeo Oncology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.